Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Gossamer Bio, Inc.NASDAQ: GOSS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $232K fell 32.2% year over year, ahead of the -74.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at -39.1% a year.
Context
- Depreciation & amortization amounted to 2.1% of revenue in FY2025, down 1.6 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -32.2% holds above the trailing-twelve-month pace of -74.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1M USD
- Year-over-year change
- -75.9%
- 4-year CAGR
- -33.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1M | -75.9% |
| FY2024 | 2024-12-31 | 4.15M | -5.3% |
| FY2023 | 2023-12-31 | 4.39M | -1.0% |
| FY2022 | 2022-12-31 | 4.43M | -14.3% |
| FY2021 | 2021-12-31 | 5.17M | — |
Depreciation & Amortization vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 depreciation & amortization of $892K is the 5th largest of the 9 companies compared; the peer median is $1.02M.
- Its year-over-year change of -74.4% is the lowest of 8, against a peer median of +11.1%.
- Depreciation & amortization amounts to 1.6% of revenue for GOSS, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $7.93M | +15.5% | +25.3% | 9.0% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Dec 2025 | $1.19M | — | — | 1.0% | |
| LTM Mar 2026 | $892K | -74.4% | -39.1% | 1.6% | |
| LTM Mar 2026 | $856K | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
| LTM Mar 2026 | $481K | +11.1% | -33.4% | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding GOSS) | $1.02M | +11.1% | +6.5% | 1.3% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 32.01M | 42.55M | 28.52M | 20.62M | 10.56M |
| Change in Working Capital | 774K | (4.46M) | (14.84M) | 39.46M | (13.63M) |
| Accounts Receivables | 0 | 0 | 0 | (5.34M) | (6.89M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.43M) | (1.81M) | 3.99M | (1.66M) | (2.75M) |
| Other Working Capital | 5.2M | (2.65M) | (18.83M) | 46.45M | (3.99M) |
| Other Non-Cash Items | 7.17M | (177K) | 2.6M | (11.17M) | 1.18M |
| Operating Cash Flow | (188.89M) | (187.03M) | (159.16M) | (3.47M) | (171.27M) |
| Capital Expenditures | (1.62M) | (475K) | 0 | 0 | (79K) |
| Acquisitions (Net) | 0 | (65K) | 0 | 0 | 0 |
| Purchases of Investments | (152.03M) | (238.06M) | (441.67M) | (494.78M) | (227.11M) |
| Sales of Investments | 36.23M | 237.5M | 330.7M | 523.8M | 383.54M |
| Other Investing Activities | (75K) | 65K | 0 | 0 | 0 |
| Investing Cash Flow | (117.43M) | (1.04M) | (110.97M) | 29.02M | 156.36M |
| Debt Repayment | 0 | (5.81M) | (11.61M) | (12.58M) | 0 |
| Common Stock Issued | 0 | 119.95M | 201.32M | 464K | 6.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 629K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.33M | 2.95M | 444K | 0 | 0 |
| Financing Cash Flow | 3.33M | 117.09M | 190.15M | (11.49M) | 6.43M |
| Effect of Forex Changes | (165K) | (517K) | 110K | (102K) | 141K |
| Net Change in Cash | (303.15M) | (71.49M) | (79.86M) | 13.97M | (8.34M) |
| Free Cash Flow | (190.51M) | (187.51M) | (159.16M) | (3.47M) | (171.35M) |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.